Cyclacel Pharmaceuticals, Inc , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.
infoCyclacel Pharmaceuticals is a micro cap stock with a total market cap of 24.68M.
infoThey trade on the NASDAQ and had their IPO 17 years and 8 months ago.
infoCyclacel Pharmaceuticals currently employs 12 people.
infoAs of Wednesday, Aug 23 2023, Cyclacel Pharmaceuticals’s share price is $12.98.
News Relating to Cyclacel Pharmaceuticals
GlobeNewsWire
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
Thursday Aug 03 2023 at 09:15
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
Seeking Alpha
Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript
Thursday May 11 2023 at 19:59
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim – IR Spiro Rombotis – CEO Mark Kirschbaum – CMO Paul McBarron – CFO Conference Call Participants Ahu Demir – Ladenburg Thalmann Shubhendu Sen Roy – Brookline Capital Markets Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
GlobeNewsWire
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
Thursday May 04 2023 at 09:15
BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thursday, May 11, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
GlobeNewsWire
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
Tuesday Mar 07 2023 at 09:15
BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript
Monday Mar 06 2023 at 21:04
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Irina Koffler – Investor Relations Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum – Senior Vice President and Chief Medical Officer Conference Call Participants Jonathan Aschoff – ROTH MKM Ahu Demir – Ladenburg Jeff Jones – Oppenheimer Kemp Dolliver – Brookline Capital Markets Operator Good afternoon and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call and Webcast. [Operator Instructions] Please note, today’s call is being recorded.
GlobeNewsWire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
Monday Feb 27 2023 at 09:15
BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2022 financial results on Monday, March 6, 2023. The Company will host a conference call at 4:30pm ET on the same day.
GlobeNewsWire
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
Monday Jan 30 2023 at 09:15
BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present an overview of Cyclacel’s business and clinical programs at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on February 6-9, 2023.
GlobeNewsWire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
Thursday Dec 15 2022 at 09:15
BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events are taking place January 9-11, 2023 in San Francisco, California.
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript
Wednesday Nov 09 2022 at 20:06
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Irina Koffler – LifeSci Advisors Spiro Rombotis – President & Chief Executive Officer Mark Kirschbaum – Senior Vice President & Chief Medical Officer Paul McBarron – Executive Vice President, Finance & Chief Operating Officer Conference Call Participants Ahu Demir – Ladenburg Jonathan Aschoff – ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2022 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
GlobeNewsWire
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
Thursday Nov 03 2022 at 09:15
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results on Wednesday, November 9, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day.
GlobeNewsWire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
Thursday Oct 13 2022 at 09:15
– Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma – – Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma –
GlobeNewsWire
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Wednesday Sep 21 2022 at 09:15
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann’s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York.
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2022 Results – Earnings Call Transcript
Wednesday Aug 10 2022 at 20:16
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Irina Koffler – LifeSci Advisors Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Chief Financial Officer and Chief Operating Officer Mark Kirschbaum – Senior Vice President and Chief Medical Officer Conference Call Participants Ahu Demir – Ladenburg Thalmann & Co Jonathan Aschoff – ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].
GlobeNewsWire
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
Wednesday Aug 03 2022 at 09:15
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results on Wednesday, August 10, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results – Earnings Call Transcript
Wednesday May 11 2022 at 20:45
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Irina Koffler – LifeSci Advisors Spiro Rombotis – President, CEO & Executive Director Paul McBarron – EVP, CFO, COO, Secretary & Executive Director Mark Kirschbaum – SVP & Chief Medical Officer Conference Call Participants Kevin DeGeeter – Oppenheimer Ahu Demir – Ladenburg Thalmann & Co. Jonathan Aschoff – ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results – Earnings Call Transcript
Monday Mar 28 2022 at 20:13
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results – Earnings Call Transcript
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results – Earnings Call Transcript
Wednesday Nov 10 2021 at 20:49
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results – Earnings Call Transcript
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results – Earnings Call Transcript
Wednesday Aug 11 2021 at 20:30
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results – Earnings Call Transcript
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results – Earnings Call Transcript
Wednesday May 12 2021 at 21:02
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results – Earnings Call Transcript
GlobeNewsWire
Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
Monday Mar 15 2021 at 07:16
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Thursday, March 18, 2021 at 9:20 AM (EDT). Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. Cyclacel will host one-on-one meetings with investors during the event.
Benzinga
Cyclacel Pharmaceuticals Presses Capital Raise Button
Friday Mar 12 2021 at 11:50
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It will raise gross proceeds of approximately $12.65 million.
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results – Earnings Call Transcript
Thursday Feb 25 2021 at 22:40
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results – Earnings Call Transcript
GlobeNewsWire
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
Monday Jan 11 2021 at 07:46
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures –
GlobeNewsWire
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
Wednesday Dec 30 2020 at 07:00
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech Showcase™ Digital 2021. The conference is taking place online between January 11-15 and will feature prerecorded sessions of company presentations. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs.
Seeking Alpha
Cyclacel Pharmaceuticals’ (CYCC) CEO Spiro Rombotis on Q3 2020 Results – Earnings Call Transcript
Wednesday Nov 11 2020 at 21:08
Cyclacel Pharmaceuticals’ (CYCC) CEO Spiro Rombotis on Q3 2020 Results – Earnings Call Transcript
GlobeNewsWire
Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
Thursday Nov 05 2020 at 09:29
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on Wednesday, November 11, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
GlobeNewsWire
Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020
Monday Oct 26 2020 at 08:26
A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib
Yahoo
Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results
Wednesday Aug 12 2020 at 20:05
\- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -BERKELEY HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel’s novel CDK2/9 inhibitor. The Company’s net loss applicable to common shareholders for the three months ended June 30, 2020 was $2.2 million. As of June 30, 2020, cash and cash equivalents totaled $25.3 million. Based on current spending, the Company estimates it has sufficient resources to fund planned operations, including research and development, through the end of 2022.“We believe fadraciclib is establishing a leadership position among MCL1 suppressing compounds in development. Our recent, peer-reviewed publication elaborates the mechanistic rationale for fadraciclib as an anti-cancer therapy signifying the benefits of inhibiting CDK2 and CDK9, two complementary cancer pathways,” said Spiro Rombotis, President and Chief Executive Officer. “We continue to be encouraged by observations of deep partial response and prolonged stable disease with tumor shrinkage as an intravenously administered monotherapy in patients with advanced solid tumors and antileukemic activity in combination with venetoclax. In parallel with evaluating fadraciclib in certain leukemias, we are executing a precision medicine strategy to evaluate the compound in patients with solid tumors with study enrollment expected to begin by the first quarter of 2021. As the global pandemic continues to unfold, our priorities are to ensure patient and employee safety and support efforts to stem COVID-19 disease as part of our corporate social responsibility. Despite the challenges we remain committed to our strategy of building an innovative pipeline addressing the rising problem of cancer resistance and achieving our clinical milestones to drive shareholder value.”Key Corporate Highlights * Announced publication of a peer-reviewed study of fadraciclib, in PLOS ONE. The publication, authored by scientists from Cyclacel and The Institute of Cancer Research, London, describes the discovery of fadraciclib and shows its ability to target CDK2 and CDK9, leading to broad therapeutic potential. * CYC065-01 Phase 1 part 2 single agent i.v. – As previously reported a heavily pretreated patient with MCL1 amplified endometrial cancer achieved a radiographically confirmed partial response (PR) after a month and a half on fadraciclib at 213mg. This patient continues on therapy for more than a year and reduction in her target tumor lesions is 83%. An additional patient with cyclin E amplified ovarian cancer achieved stable disease with 29% tumor shrinkage after approximately four months at 213mg. We have submitted data for publication at a cancer conference later in the year. * Based on data thus far, we are designing a Phase 1/2 precision medicine study to further evaluate fadraciclib as monotherapy and in combinations in patients with advanced solid tumors. * CYC065-01 Phase 1 part 3 single agent p.o. – Initial data from an oral capsule formulation of fadraciclib given once daily to four patients with advanced solid tumors demonstrated a predictable pharmacokinetic profile closely overlapping the intravenous form with encouraging exposure levels. * CYC065-03 Phase 1 fadraciclib i.v. and venetoclax p.o. in AML/MDS – We have dosed 11 heavily pretreated patients with relapsed/refractory (R/R) AML in five dose levels up to 200 mg/m2 of fadraciclib in combination with venetoclax. Evidence of anticancer activity has been observed in four out of eleven patients treated. Preclinical data in AML suggest that targeting both MCL1 and BCL2 may be more beneficial than inhibiting either protein alone. * CYC065-02 Phase 1 fadraciclib i.v. and venetoclax p.o. in CLL – We have dosed 5 patients with R/R CLL in four dose levels up to 150 mg/m2 of fadraciclib in combination with venetoclax. Evidence of anticancer activity has been observed in two patients who achieved MRD negativity on the combination. Preclinical data suggest that targeting both BCL2 and MCL1 in CLL may be more beneficial than single agent treatment in this setting as well. * CYC682-11 Phase 1 part 2 sapacitabine p.o. and venetoclax p.o. – We have enrolled 12 patients in a dose escalation study in our DNA Damage Response (DDR) program evaluating an oral combination of sapacitabine and venetoclax in patients with R/R AML/MDS. Two patients, previously treated with combination therapies including hypomethylating agents, have achieved 5 and 6 cycles of treatment respectively. Sapacitabine is a nucleoside analogue that is active in AML and MDS R/R to prior therapy such as cytarabine or hypomethylating agents. Preclinical data demonstrated synergy of sapacitabine with BCL2 inhibition, which may offer an effective, oral treatment regimen for patients who have failed front-line therapy. * CYC140-01 Phase 1 CYC140 i.v. – We have enrolled 6 patients in our first-in-human, dose escalation study evaluating CYC140 in patients with advanced leukemias. CYC140 is a small molecule, selective polo-like-kinase 1 (PLK1) inhibitor that has demonstrated potent and selective target inhibition and high activity in xenograft models of human cancers. In addition to hematological malignancies we are evaluating studies of CYC140 in solid tumors.More information on our clinical trials can be found here.Key Business Objectives * Report updated fadraciclib Phase 1 safety and efficacy data with frequent i.v. dosing schedule in patients with advanced solid cancers; * Report initial safety and PK data from Phase 1 study of fadraciclib oral formulation; * Treat first patient in fadraciclib Phase 1/2 precision medicine study; * Report initial data from fadraciclib-venetoclax Phase 1 study in R/R AML/MDS & CLL; * Report initial data from sapacitabine-venetoclax Phase 1 study in R/R AML/MDS; * Report initial data from CYC140 Phase 1 first-in-human study in R/R leukemias; and * Report data from Phase 1b/2 sapacitabine-olaparib IST in BRCA mutant metastatic breast cancer when reported by the investigators.Financial HighlightsAs of June 30, 2020, cash and cash equivalents totaled $25.3 million, compared to $11.9 million as of December 31, 2019. The increase of $13.4 million was primarily due to net proceeds of $18.3 million from an equity financing in April 2020 and net cash used in operating activities of $4.7 million. There were no revenues for each of the three months ended June 30, 2020 and 2019.Research and development expenses were $1.2 million for each of the three months ended June 30, 2020 and 2019. Research and development expenses relating to transcriptional regulation increased by approximately $0.2 million for the three months ended June 30, 2020 as we continue to progress the clinical evaluation of fadraciclib.General and administrative expenses for the three months ended June 30, 2020 were $1.3 million, compared to $1.2 million for the same period of the previous year.Total other income, net, for the three months ended June 30, 2020 was $20,000, compared to $0.2 million for the same period of the previous year. The decrease of approximately $0.2 million for the three months ended June 30, 2020 is primarily related to income received under an Asset Purchase Agreement with Thermo Fisher Scientific Inc.United Kingdom research & development tax credits were $0.3 million for each of the three months ended June 30, 2020 and 2019.Net loss for the three months ended June 30, 2020 was $2.2 million compared to $1.8 million for the same period in 2019.The Company estimates that cash resources of $25.3 million as of June 30, 2020 will fund currently planned programs through 2022.Conference call information:US/Canada call: (877) 493-9121 / international call: (973) 582-2750 US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406 Code for live and archived conference call is 2477369.For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at http://www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days. About Cyclacel Pharmaceuticals, Inc.Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors and in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is evaluating an oral combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An investigator-sponsored trial (IST) is evaluating an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit http://www.cyclacel.com.Forward-looking StatementsThis news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
Yahoo
Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results
Wednesday Aug 05 2020 at 11:00
BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results on Wednesday, August 12, 2020. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call: (877) 493-9121 / international call: (973) 582-2750 US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406 Code for live and archived conference call is 2477369.For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at http://www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days. About Cyclacel Pharmaceuticals, Inc.Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors and in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is evaluating an oral combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An investigator-sponsored trial (IST) is evaluating an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.Forward-looking StatementsThis news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts for Cyclacel Pharmaceuticals, Inc.Company: Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com Investor Relations: Russo Partners LLC, Jan Medina, (646) 942-5632, Jan.Medina@russopartnersllc.com© Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
Yahoo
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
Tuesday Jul 28 2020 at 15:46
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
Cyclacel Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Cyclacel Pharmaceuticals’s Altman Z-score is -27.77 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Cyclacel Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Cyclacel Pharmaceuticals.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Cyclacel Pharmaceuticals’s Income Quality of 0.91 is greater than its Industry Group of 0.69 (31.9% greater)
Cyclacel Pharmaceuticals’s Income Quality of 0.91 is greater than its Major Industry Group of 0.71 (28.2% greater)
Cyclacel Pharmaceuticals’s Income Quality of 0.91 is greater than its Sector of 0.75 (21.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Cyclacel Pharmaceuticals’s Current Ratio of 2.59 is lower than its Industry Group of 4.76 (-45.6% lower)
Cyclacel Pharmaceuticals’s Current Ratio of 2.59 is lower than its Major Industry Group of 4.32 (-40.0% lower)
Cyclacel Pharmaceuticals’s Current Ratio of 2.59 is in line with its Sector of 2.6 (-0.4% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.08 & -1.27)
Cannot compare a negative PE Ratio (-1.08 & -1.1)
Cannot compare a negative PE Ratio (-1.08 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cyclacel Pharmaceuticals’s PB Ratio of 1.69 is greater than its Industry Group of 1.34 (26.1% greater)
Cyclacel Pharmaceuticals’s PB Ratio of 1.69 is greater than its Major Industry Group of 1.4 (20.7% greater)
Cyclacel Pharmaceuticals’s PB Ratio of 1.69 is in line with its Sector of 1.62 (4.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cyclacel Pharmaceuticals’s ROE of -1.56 is lower than its Industry Group of -0.44 (-254.5% lower)
Cyclacel Pharmaceuticals’s ROE of -1.56 is lower than its Major Industry Group of -0.38 (-310.5% lower)
Cyclacel Pharmaceuticals’s ROE of -1.56 is lower than its Sector of -0.03 (-5100.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cyclacel Pharmaceuticals’s ROCE of -1.93 is lower than its Industry Group of -0.42 (-359.5% lower)
Cyclacel Pharmaceuticals’s ROCE of -1.93 is lower than its Major Industry Group of -0.37 (-421.6% lower)
Cyclacel Pharmaceuticals’s ROCE of -1.93 is lower than its Sector of -0.04 (-4725.0% lower)
Derived from SEC.GOV filing dataopen_in_new